Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).  TK2d is caused by a genetic mutation in the TK2 gene. This mutation leads to a decrease in mitochondrial DNA […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!